Semaglutide Improves Liver Fibrosis in New Trial Analysis
Two separate phase 3 trials show that semaglutide improved fatty liver disease and reduced hospitalizations related to cardiovascular risk in...
analysis
Economic Analysis Supporting Significant Hospitalization
Data illustrate the potential of QUELIMMUNE™️ with cost neutrality starting at 6 days of therapy and a significant reduction in...
The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL)
Study design and participantsIn this study, we retrieved data of patients initially diagnosed with HCC between January 2018 and December...
